The future of cancer
diagnostics is now

WE IDENTIFY GENETIC CAUSES OF CANCER

The most powerful
biomarker discovery platform

GEMMAai™

GEnoMic Marker Analyzer

AI-Powered platform for matching patients with right treatment

GEMMAai for clinical trial enrolment – available *
GEMMAai for companion diagnostics development – available *
GEMMAai for patients coming soon – pipeline *

TUMOR
TYPE

TUMOR GENOMES

TARGETED THERAPY

DISCOVERY

PROTOTYPE ASSAY

ANALITYCAL VALIDATION

CLINICAL VALIDATION

REGULATORY APPROVAL

UPCOMING
MILESTONES

BREAST

2152

CDK4/6i
Ant-HER2
PARPi
mTORi
PIK3i

Title

65%

Title

65%

Title

45%

Title

15%

Title

15%

2 analytically validated diagnostic tools in Q1 2021

OVARIAN

512

Carboplatin / PARPi

Title

65%

FDA breakthrough device submission Q2 2021

FASETM

GENOMIC FEATURE DATABASE

YOUR inhibitor

Discovery and validation

AI-POWERED
STRATIFICATION DIAGNOSTIC TOOL

Learn more

* For Research Use Only. Not for use in diagnostic procedures.

TUMOR TYPE: OVARIAN

WGS DATA

512

TARGETTED THERAPY

Carboplatin / PARPi

65%

UPCOMING MILESTONES

FDA breakthrough device in Q3 2021

TUMOR TYPE: BREAST

WGS DATA

2152

TARGETTED THERAPY

PARPi

65%

CDK4/6i

25%

Ant-HER2

45%

mTORi

15%

PIK3i

15%

UPCOMING MILESTONES

2 analytically validated diagnostic tools in Q1 2021

TUMOR TYPE: LUNG

WGS DATA

1852

TARGETTED THERAPY

PARPi

10%

immunotherapy

10%

UPCOMING MILESTONES

2 prototype assays in Q3 2021

FUSETM

WGS DATA

GENOMIC FEATURE DATABASE

TARGETTED THERAPY

YOUR inhibitor

DISCOVERY AND VALIDATION

AI-POWERED STRATIFICATION DIAGNOSTIC TOOL

News

14 May 2021 in News

BiO€QUITY Europe on 17-19 May 2021

MNM Diagnostics has developed a unique AI-powered platform allowing for the rapid development of genome-based biomarkers providing an accurate prediction of the treatment outcomes for cancer patients. To date, we…
Read More
9 April 2021 in News

Certificate of Approval ISO 9001:2015

MNM Diagnostics received Certificate of Approval to the standards ISO 9001:2015, which means we meet requirements of the management standards in the organization in the field of : "Banking and…
Read More
13 January 2021 in News

The success of Polish scientists. Research on COVID-19 has been recognized as one of the most remarkable discoveries in 2020 by Nature

Research indicating the genetic background of the severe illness in COVID-19 cases, co-authored by Dr. Paweł Zawadzki from MNM Diagnostics and the Polish Biobanking Center, was among the most remarkable…
Read More
13 January 2021 in News

ICZMP in Łódź: whole-genome diagnostics for patients with breast and ovarian cancer

Patients of the Polish Mother's Memorial Hospital Research Institute in Łódź have gained access to a cancer diagnosis method based on tumor DNA analysis. ICZMP signed an agreement on this…
Read More

Our publications

Partners

Any questions?

Contact us

    I have read and agree to privacy policy and terms of service
    privacy policy | terms of service

    In a hurry?

    Download a leaflet



      I'm a patientI'm a doctorI'm a student
      I have read and agree to privacy policy and terms of service
      privacy policy
      terms of servic